GenVec (GNVC) Announces SBIR Grant Approval from NIAID
GenVec (www.genvec.com), a biopharmaceutical company developing novel therapeutic drugs and vaccines, announced that it has received a Phase I Small Business Innovation and Research grant from the National Institute of Allergy and Infectious Diseases of the National Institutes of Health to assist GenVec’s work to create novel adenovector-based vaccines for HSV-2 (a virus of genital herpes). The SBIR grant will support development being administrated at Gen Vec, the Vaccine and Infectious Disease Institute at Fred Hutchingson Cancer Research Center, and the University of Washington. Dr. Rick King, GenVec’s Senior Vice President of Research and Development commented, “HSV-2 continues to be…